Who are Indometacin Cataplasms's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aspirin monotherapy, Diclofenac Sodium Topical Gel, 1%, Topical NSAID, High Dose Ibuprofen, lysine acetylsalicylate, Ibuprofen Tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/indometacin-cataplasms.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Indometacin Cataplasms — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Indometacin Cataplasms (Indometacin Cataplasms) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Rheumatology / Pain Management / Inflammation.

marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) Rheumatology / Pain Management / Inflammation Small molecule Live · refreshed every 30 min

Target snapshot

Indometacin Cataplasms (Indometacin Cataplasms) — Guang'anmen Hospital of China Academy of Chinese Medical Sciences. Indomethacin, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain when applied topically as a cataplasm (poultice).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Indometacin Cataplasms TARGET	Indometacin Cataplasms	Guang'anmen Hospital of China Academy of Chinese Medical Sciences	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Aspirin monotherapy	Aspirin monotherapy	Harbin Medical University	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Diclofenac Sodium Topical Gel, 1%	Diclofenac Sodium Topical Gel, 1%	Amneal Pharmaceuticals, LLC	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Topical NSAID	Topical NSAID	University of Nottingham	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and/or COX-2)
High Dose Ibuprofen	High Dose Ibuprofen	Ottawa Hospital Research Institute	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
lysine acetylsalicylate	lysine acetylsalicylate	Azienda Ospedaliera San Giovanni Battista	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Ibuprofen Tablets	Ibuprofen Tablets	Overseas Pharmaceuticals, Ltd.	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

Università degli Studi di Brescia · 4 drugs in this class
Bausch & Lomb Incorporated · 4 drugs in this class
Bayer · 3 drugs in this class
Pfizer · 3 drugs in this class
Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
Organon and Co · 3 drugs in this class
Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
Bezmialem Vakif University · 2 drugs in this class
Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
Center For Excellence In Eye Care · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Indometacin Cataplasms — Competitive Intelligence Brief. https://druglandscape.com/ci/indometacin-cataplasms. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing